The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Ursodeoxycholic Acid in Cholestasis: Potential Mechanisms of Action and Therapeutic Applications
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448
Self-citation
Cited by
The Continuing Importance of Bile Acids in Liver and Intestinal Disease
Hofmann, A. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2647 · Cited by 982
Paumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
“Experimental evidence suggests three major mechanisms of action: (1) protection of cholangiocytes against cytotoxicity of hydrophobic bile acids, resulting from modulation of the composition of mixed phospholipid-rich micelles, reduction of bile acid cytotoxicity of bile and, possibly, decrease of the concentration of…”
BackgroundSelf-citationEpidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.025 · Cited by 632
Self-citationIntrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management
Lammert, F., Marschall, H.-U., Glantz, A., & Matern, S. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80139-7 · Cited by 524
Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417
“supporting the concept that TUDCA might exert its anticholestatic effects in part through Ca 2+ -dependent and PKC-dependent mechanisms”
BackgroundSelf-citationBile acids: regulation of apoptosis by ursodeoxycholic acid
Amaral, J. D., Viana, R. J. S., Ramalho, R. M., Steer, C. J., & Rodrigues, C. M. P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900011-jlr200 · Cited by 363
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis
Rosmorduc, O., Poupon, R., & Hermelin, B. (2001) · Gastroenterology · doi:10.1053/gast.2001.23947 · Cited by 338
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315
Fickert, P., Zollner, G., Fuchsbichler, A., Stumptner, C., Weiglein, A. H., Lammert, F., Marschall, H., Tsybrovskyy, O., Zatloukal, K., Denk, H., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35948 · Cited by 313
Emerging roles of bile acids in mucosal immunity and inflammation
Chen, M. L., Takeda, K., & Sundrud, M. S. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0162-4 · Cited by 298
Rodrigues, C. M., Ma, X., Linehan-Stieers, C., Fan, G., Kren, B. T., & Steer, C. J. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400560 · Cited by 260
Fickert, P., Zollner, G., Fuchsbichler, A., Stumptner, C., Pojer, C., Zenz, R., Lammert, F., Stieger, B., Meier, P. J., Zatloukal, K., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.25542 · Cited by 257
Animal models to study bile acid metabolism
Li, J., & Dawson, P. A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.011 · Cited by 255
Kondrackiene, J., Beuers, U., & Kupcinskas, L. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.019 · Cited by 247
Self-citationHigh-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242
Rius, M., Hummel-Eisenbeiss, J., Hofmann, A. F., & Keppler, D. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00354.2005 · Cited by 144
Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation
Poupon, R. (2015) · Hepatology · doi:10.1002/hep.27715 · Cited by 120
“Other involved mechanisms may include antiapoptotic, antioxidant, and immune-modulating properties.(94,95) However, there is no experimental evidence that UDCA is capable of directly influencing the negative effects of proinflammatory mediators on ductal choleresis.”
BackgroundHuang, F., Pariante, C. M., & Borsini, A. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.09.021 · Cited by 117
Rust, Sauter, Oswald, Büttner, Kullak‐Ublick, Paumgartner, & Beuers (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00606.x · Cited by 64
Metadata
- Authors
- Beuers, U., Boyer, J. L., & Paumgartner, G.
- Venue
- Hepatology
- Published
- 1998-12
- Volume
- 28
- Issue
- 6
- Pages
- 1449-1453
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2003418647
- Cited by
- 220
- References
- 6
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.